Results 121 to 130 of about 192,887 (307)

Real‐World Outcome of Coronary Orbital Atherectomy in Diabetic Versus Non‐Diabetic Patients: A Single‐Center Experience

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background and Aims Clinical trial research on the safety and efficacy of coronary orbital atherectomy (OA) in diabetics compared to non‐diabetics is limited. This single‐center study aimed to perform a diabetic comparative analysis using real‐world data.
Benjamin Klein   +9 more
wiley   +1 more source

VERMONT: Vessel Fractional Flow Reserve (vFFR) Assessment of Stenosis Severity: A Prospective Study

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Vessel fractional flow reserve (vFFR) is an angiogram‐based technique validated in early studies; however, data on its real‐time diagnostic performance and integration into routine workflow remain limited. Aims The VERMONT study evaluated the diagnostic accuracy and time efficiency of real‐time vFFR versus conventional wire‐based ...
Daniel Akrawi   +15 more
wiley   +1 more source

Clinical Impact of Concordant and Discordant Physiology Parameters Post‐Percutaneous Coronary Intervention in the EASY‐PREDICT Study

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background In the EASY‐PREDICT Study, patients were randomized to angiography‐guidance or post‐percutaneous coronary intervention (PCI) physiology‐guidance. Discordance between resting and hyperemic physiology post‐PCI might have a different relationship with clinical outcomes.
Paola Ulacia Flores   +13 more
wiley   +1 more source

Population Pharmacokinetic and Exposure‐Response Analysis of the Cognitive Effects of TAK‐071 in Participants With Parkinson Disease and Cognitive Impairment

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract TAK‐071 is a novel muscarinic M1 positive allosteric modulator under investigation for the treatment of cognitive impairment and falls associated with Parkinson disease (PD). This study evaluated population pharmacokinetics of TAK‐071 following single (1‐160 mg) and multiple (3‐15 mg once daily) oral‐dose TAK‐071 in 112 healthy participants ...
Hongxia Jia   +8 more
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective 5‐hydroxytryptamine 2C (5‐HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double‐blind, placebo‐controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and ...
Rosa Chan   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy